AstraZeneca And Huma On Digital’s Value For Pharma
Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.
You may also be interested in...
Health care is undergoing a transformation as more and more treatments become partially-digitized. However, building the platforms required is difficult, meaning many companies call for third-party help. Medtech Insight spoke to one player in this space, Mobiquity, to learn more about the process.
The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.